Related Experiment Video
Updated: May 11, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Research Article: The Aromatase Gene rs10046 T>C Polymorphism Does Not Contribute to the Risk of Breast Cancer: A
Manju Patel1, Arifullah Mohammed2, Mohammad Khairul Azhar Abdul Razab3
1Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, Chhattisgarh, India.
None:
Breast cancer is the most common cancer diagnosed in women. Increased exposure to oestrogens is one of the major risk factors for breast cancer. The synthesis of estrogens is mediated by the aromatase enzyme that encoded by CYP19A1 gene. Further, highest aromatase activities were documented in tumor-associated stroma tissues of breast. Genetic polymorphisms in CYP19A1 gene are known to modulate the estradiol and to the estradiol/testosterone ratio. The rs10046 T>C polymorphism in the 3' untranslated region of CYP19A1 gene has been linked to the risk of breast cancer. The studies conducted till date are not consistent in reporting the association of rs10046 polymorphism with breast cancer. In the present study, we have conducted a meta-analysis of data available for CYP19A1 rs10046 T>C and breast cancer from 23 studies. The outcome of the present meta-analysis showed that there is no association between rs10046 polymorphism and breast cancer risk in all genetic models [C vs. T: odds ratio (OR) = 0.99, confidence interval (CI) = 0.88-1.23; CC vs. TC + TT: OR = 1.02, CI = 0.88-1.18; TC + CC vs. GG: OR = 0.97, CI = 0.80-1.17]. Further, ethnicity based subgroups also failed to show the association between breast cancer and rs10046. Begg's funnel plots and Egger's tests did not reveal evidence for publication bias (Egger's P value = 0.832). In summary, the rs10046 T>C polymorphism on CYP19A1 is not a major risk factor for breast cancer.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
The Ras Gene
Ras is a superfamily...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

